MOPP/ABVD FOLLOWED BY RADIOTHERAPY FOR MASSIVE MEDIASTINAL HODGKIN'S DISEASE

众所周知，患有巨大纵隔霍奇金病的患者 对治疗的反应比其他霍奇金病患者差一些。这 设计了一项试验，以提高反应率和无病生存率 任何阶段的巨大纵隔霍奇金病患者。患者 在本研究中，在放射治疗之前， 开始化疗，包括两个非化疗周期的交替， 交叉耐药方案，MOPP和ABVD，共6个月， 疗法化疗后完全缓解的患者 接受放射治疗的新方法。第一个10 Gy是 给药到疾病的原始程度，并额外给予35- 40 Gy， 输送到任何残留的纵隔肿块。迄今为止，有65个可评估的 55例（85%）患者获得完全缓解。已有10 复发（18%）。13名患者死亡，其中一名与治疗有关 肺炎。这些结果是在这方面取得的最好结果。 何杰金氏病患者的亚组。

Patients with massive mediastinal Hodgkin's disease are known to have a somewhat poorer response to treatment than other Hodgkin's patients. This trial was designed to improve the response rate and disease-free survival of patients with any stage massive mediastinal Hodgkin's disease. Patients on this study are fully staged and simulated for radiation therapy prior to beginning chemotherapy, which consists of alternating cycles of two non- cross-resistant regimens, MOPP and ABVD for a total of six months of therapy. Patients who are in complete remission following chemotherapy receive radiation therapy delivered in a novel way. The first lOGy are administered to the original extent of disease and an additional 35-4OGy is delivered to any residual mediastinal mass. To date, there are 65 evaluable patients, 55 (85%) achieved a complete response. There have been 10 relapses (18%). Thirteen patients have died, one with a treatment related pneumonitis. These results are the best that have been obtained in this subgroup of patients with Hodgkin's disease.